UNSPSC 51112901: Amifostine

This classification denotes a cytoprotective agent with the molecular formula C5H15N2O3PS.3H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier M487QF2F4V, chemically known as 2-((3-aminopropyl)amino)-ethanethiol, dihydrogen phosphate ester (9ci) but more generally known as amifostine, which bears US NIH Compound Identifier 2141. Amifostine most often comes in base, ethiofos, and hyrdate forms. European Medicines Agency schedules Amifostine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12846MIG.

UNSPSC 51112901 Amifostine is a Commodity code covering a chemotherapy adjuvant pharmaceutical used to reduce treatment toxicity in cancer patients. State and local procurement activity under this code reflects purchases by public health departments, county hospitals, and regional cancer centers acquiring amifostine for use during chemotherapy regimens, particularly to mitigate kidney and bone marrow damage in patients undergoing cisplatin-based treatments. The sourcing mix includes state health agencies managing oncology programs, county-operated hospital systems, and specialized public cancer treatment facilities. Procurement typically occurs through standing pharmaceutical contracts negotiated by state purchasing offices or cooperative purchasing arrangements, with units ordered as needed to support patient care protocols.

The source provided contains no recent state and local contract opportunities tagged to this code. Activity under UNSPSC 51112901 does not appear in the available market record, suggesting either minimal recent solicitation volume or that amifostine procurement occurs primarily through existing framework agreements rather than discrete RFPs or IFBs.